Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
OLUMIANT (baricitinib) continues to demonstrate a consistent safety profile in a long-term analysis involving 3,770 rheumatoid arthritis (RA) patients across 14,744 patient years of exposure. The overall incidence rate of adverse events stood at 22.6 per 100 patient years, with serious adverse events at 7.4. Safety results will be presented by Eli Lilly and Company and Incyte at ACR Convergence 2021. A real-world study in Japan involving 3,445 RA patients also showed no new safety signals, reinforcing OLUMIANT's safety over 24 weeks. OLUMIANT is approved in over 75 countries for RA treatment.
The EMPEROR-Preserved phase III trial revealed that Jardiance (empagliflozin) significantly reduces the risk of cardiovascular death or hospitalization for heart failure and slows kidney function decline in adults with heart failure and left ventricular ejection fraction (LVEF) over 40%. Presented at the American Society of Nephrology Kidney Week 2021, findings showed consistent benefits regardless of chronic kidney disease (CKD) status. The trial included nearly 6,000 adults, with results highlighting the potential for Jardiance as a viable treatment option. Fast Track and Breakthrough Therapy designations have been granted for its cardiovascular applications.
Loxo Oncology at Lilly announced the upcoming presentation of data from the pirtobrutinib development program at the ASH Annual Meeting, scheduled for December 11-14, 2021. Pirtobrutinib is a reversible BTK inhibitor currently undergoing clinical trials for chronic lymphocytic leukemia and mantle cell lymphoma. Oral presentations will feature updated results from the Phase 1/2 BRUIN trial, focusing on patients previously treated for these conditions. The trials highlight the drug's potential efficacy and innovative mechanism against acquired resistance.
Eli Lilly announced an agreement with the U.S. government to supply 614,000 doses of bamlanivimab with etesevimab, a COVID-19 treatment, for $1.29 billion. The deal is expected to add approximately $840 million in revenue and 25 cents per share to Lilly's 2021 earnings. The doses will be delivered by January 31, 2022, with a minimum of 400,000 by December 31, 2021. Bamlanivimab and etesevimab are authorized under Emergency Use Authorization for specific COVID-19 cases but are not FDA-approved. The supply is supported by federal funds under a BARDA contract.
Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Key executives including Jake Van Naarden, Mark Mintun, and Jamie Croaning will engage in a virtual fireside chat at 12:30 p.m. Eastern time. Investors can access a live audio webcast via Lilly's Investor website, with a replay available for 90 days. Lilly aims to improve global health care through innovative medicines and community support, continuing a mission established over a century ago. For more details, visit www.lilly.com.
On October 28, 2021, Eli Lilly announced the publication of overall survival data from the Phase 3 monarchE study of Verzenio (abemaciclib) in the Annals of Oncology. This study explores the effectiveness of Verzenio in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. Notably, the FDA approved Verzenio in combination with endocrine therapy for specific patient populations earlier in the month. Although the overall survival data are still immature, they are pivotal for ongoing evaluations of Verzenio's efficacy.
Eli Lilly reported third-quarter 2021 revenues of $6.773 billion, an 18% increase from 2020, driven by a 35% rise in revenue from newer medicines. Net income was $1.110 billion, with reported EPS of $1.22, an 8% decline year-over-year. Non-GAAP EPS increased 38% to $1.94. The company announced several drug approvals and regulatory submissions, enhancing its growth potential. Lilly expects full-year revenue between $27.2 billion and $27.6 billion, reflecting strong performance in key products despite a projected decline in certain older therapies.
Eli Lilly's tirzepatide demonstrates significant efficacy in managing type 2 diabetes, showcasing superior reductions in A1C and body weight compared to insulin glargine in the SURPASS-4 trial. Over 52 weeks, the highest dose of tirzepatide resulted in a 2.58% A1C reduction and an 11.7 kg weight loss. Safety profiles remained consistent with gastrointestinal side effects being most common. The trial, involving 2,002 participants, confirmed tirzepatide's effectiveness and safety over 104 weeks, indicating promising long-term management for patients with increased cardiovascular risk.
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a fourth-quarter dividend of $0.85 per share on outstanding common stock. This dividend is scheduled for payment on December 10, 2021, to shareholders on record as of November 15, 2021. Eli Lilly continues its commitment to improving healthcare through innovative medicines while balancing business growth and shareholder returns.
Eli Lilly and Company (NYSE: LLY) has announced promising results from the Phase 3 monarchE trial for Verzenio® (abemaciclib) in treating high-risk early breast cancer. The study demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) after a median follow-up of 27 months. At three years, IDFS improved by 5.4%, while DRFS improved by 4.2%. The data suggests that adding Verzenio to endocrine therapy could revolutionize treatment for patients at high risk of recurrence. Safety profiles remained consistent with known data.